Who Owns Lexeo Therapeutics Stock?
NASDAQ: LXEOHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Ownership breakdown
- Held by institutions
- 117.44%
- Institutions (% of float)
- 118.19%
- Held by insiders
- 0.63%
- Institutional holders
- 198
- Institutions 99.4%
- Insiders 0.6%
- Public and other 0.0%
Who owns Lexeo Therapeutics stock?
Institutional investors own about 117.4% of Lexeo Therapeutics's shares, spread across 198 institutions that file 13F reports. That level of institutional ownership is high, typical of large, widely followed companies. Insiders, including executives, directors and large founding shareholders, hold 0.63% of LXEO.
The largest institutional holders are Affinity Asset Advisors, Llc (8.75%), Montanova Capital LLC (7.71%) and Blackrock Inc. (7.22%). Together, the top 10 institutions control 60.8% of shares outstanding. In their latest filings, 6 of the top 10 institutions increased their LXEO positions and 0 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of LXEO
| Institution | Shares | % Held | Change |
|---|---|---|---|
| Affinity Asset Advisors, Llc | 7.25M | 8.75% | +24.8% |
| Montanova Capital LLC | 6.38M | 7.71% | 0.0% |
| Blackrock Inc. | 5.97M | 7.22% | +4.1% |
| RA Capital Management, L.P. | 5.00M | 6.04% | 0.0% |
| Frazier Life Sciences Management, L.P. | 4.82M | 5.83% | 0.0% |
| JPMORGAN CHASE & CO | 4.58M | 5.54% | +4659.8% |
| Vestal Point Capital, LP | 4.32M | 5.22% | 0.0% |
| Citadel Advisors Llc | 4.24M | 5.12% | +8.7% |
| Balyasny Asset Management LP | 3.99M | 4.82% | +65.3% |
| Millennium Management Llc | 3.78M | 4.56% | +33.4% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of LXEO
| Fund | Shares | % Held |
|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.34M | 2.82% |
| iShares Trust-iShares Russell 2000 ETF | 1.86M | 2.24% |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 1.58M | 1.91% |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 776.53K | 0.94% |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 715.41K | 0.86% |
| abrdn Life Sciences Investors | 675.09K | 0.82% |
| iShares Trust-iShares Russell 2000 Value ETF | 668.37K | 0.81% |
| SPDR SERIES TRT-State Street SPDR S&P Kensho New Economies Composite E | 563.76K | 0.68% |
| iShares Trust-iShares Biotechnology ETF | 539.13K | 0.65% |
| VANGUARD SCOTTSDALE FUNDS-Vanguard Russell 2000 Index Fund | 405.17K | 0.49% |
Frequently asked questions
Who is the largest shareholder of Lexeo Therapeutics?
Affinity Asset Advisors, Llc is the largest institutional shareholder of LXEO, owning 8.75% of shares outstanding (7.25M shares) as of its latest 13F filing.
What percentage of Lexeo Therapeutics is owned by institutions?
Institutions own about 117.4% of LXEO shares and 118.2% of the public float.
How much of Lexeo Therapeutics do insiders own?
Insiders, such as officers and directors, own about 0.63% of LXEO shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.